There are more than a dozen drugs in important cancer treatment areas that are not available in India. The new drug flow into India has slowed down significantly and it is a matter of concern for oncologists and cancer patients.

The exchange, Asia's oldest, will include Axis Bank in the S&P BSE Sensex and Aditya Birla Nuvo in the S&P BSE 100 index effective December 23.

In reply to allegations made by Novartis on India's 'discriminatory' patent practices, the government has said global firms have benefited more from the country's rules than suffer from them.

The Intellectual Property Appellate Board (IPAB) has revoked the patent granted to the British drug major GlaxoSmithKline Pharma for its breast cancer drug Tykerb.

German drug major Bayer AG on Friday said it \"disagrees\" with a US court ruling that allowed Indian rival Lupin to sell generic version of its oral contraceptive (OC) tablet 'Yaz' in the American market and is \"evaluating\" options.

The Supreme Court decision on Glivec sets the tone for other patent disputes and puts global drugmakers on the back foot.

The Intellectual Property Appellate Board had denied the patent right for the drug to Novartis in 2006. The Swiss pharma major had in 2009 taken its challenge against a law that bans patents on newer forms of known drugs to the Supreme Court.

Novartis and many companies see the final decision on Glivec, whose generic versions are currently sold in the Indian market, as a landmark judgment for it would bring clarity on the interpretation and implementation of the Indian Patents Act.

Bayer AG  will approach the high court in Mumbai against a ruling by Intellectual Property Appellate Board that upheld the compulsory licence issued to India's Natco Pharma to make and sell a low-cost generic of the German drug major's patented cancer drug Nexavar.

The Intellectual Property Appellate Board has rejected Bayer AG's plea to stop Natco Pharma from producing a cheaper generic version of its patented cancer drug.

Biocon is eyeing Rs 100 cr in sales in the next four years from psoriasis drug that it plans to launch under the brand Alzumab in the country in the current year.

The key finding of the study is that despite the significant increase in wages in recent years in India on account of NREGA and other factors, wage rates for certain activities and categories of workers are still below legal minimum levels.

Indian Patents Office has revoked a patent for an asthma drug held by US-based Merck & Co following a challenge from domestic pharma firm Cipla.

Sir Richard Branson will still own more than half of Virgin Atlantic, which will continue to fly as a separate airline under its own name.

The Intellectual Property Appellate Board's decision to deny patent protection to AstraZeneca for its lung cancer drug Gefitinib is the latest setback for global pharmaceutical companies in India.

Intellectual Property Appellate Board (IPAB) has again turned down drug firm AstraZeneca's plea for a patent on the lung cancer drug Gefitinib.

The deal, when concluded, will give Cipla more access to the region and a direct, customer-facing presence in a key export market. Medpro would be the biggest international acquisition by the company, though not the first - officials confirm that its already has stakes in some foreign companies.

The pharma company slashed prices of its three generic cancer drugs - Erlocip, Docetax and Capegard - by up to 64 per cent.

India's Intellectual Property Appellate Board has revoked the patent granted in India to F. Hoffmann-La Roche AG (Roche) for pegylated interferon alfa-2a, a medicine used to treat hepatitis C, citing lack of evidence that the drug was better than existing treatments available in the market.

Of late, the heads of a number of regulatory bodies have been flexing their muscles in different ways, using the full extent of their powers in a manner their predecessors had never done.